Liquid Biopsy
News and reporting on cell-free DNA testing.
Guardant Health Lays off 7 Percent of Workforce
In a statement, Guardant Health cited the need to balance innovation with "financial discipline and focused execution" in the current economic environment.
New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions
Premium
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.
The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.
Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer
The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.